JPWO2020243135A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243135A5 JPWO2020243135A5 JP2021570274A JP2021570274A JPWO2020243135A5 JP WO2020243135 A5 JPWO2020243135 A5 JP WO2020243135A5 JP 2021570274 A JP2021570274 A JP 2021570274A JP 2021570274 A JP2021570274 A JP 2021570274A JP WO2020243135 A5 JPWO2020243135 A5 JP WO2020243135A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- membered monocyclic
- ocf
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- 150000001875 compounds Chemical class 0.000 claims description 109
- 229910052739 hydrogen Inorganic materials 0.000 claims description 79
- 125000002619 bicyclic group Chemical group 0.000 claims description 67
- 125000002950 monocyclic group Chemical group 0.000 claims description 67
- 125000003118 aryl group Chemical group 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 52
- 125000005842 heteroatom Chemical group 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000004188 dichlorophenyl group Chemical group 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 230000000269 nucleophilic effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims description 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 4
- 108091007960 PI3Ks Proteins 0.000 claims description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 4
- 101100495923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr2 gene Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 102000002689 Toll-like receptor Human genes 0.000 claims description 4
- 108020000411 Toll-like receptor Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 claims description 3
- FVKFHMNJTHKMRX-UHFFFAOYSA-N 3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidine Chemical compound C1CCN2CCCNC2=N1 FVKFHMNJTHKMRX-UHFFFAOYSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 claims description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
- 102000004452 Arginase Human genes 0.000 claims description 2
- 108700024123 Arginases Proteins 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 2
- 108020004638 Circular DNA Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 229940123014 DNA polymerase inhibitor Drugs 0.000 claims description 2
- 102100031780 Endonuclease Human genes 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 claims description 2
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 claims description 2
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 2
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 claims description 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 2
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 claims description 2
- 108010078233 Thymalfasin Proteins 0.000 claims description 2
- 108010046075 Thymosin Proteins 0.000 claims description 2
- 102000007501 Thymosin Human genes 0.000 claims description 2
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 2
- 229960004231 thymalfasin Drugs 0.000 claims description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims 1
- 108010089610 Nuclear Proteins Proteins 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- -1 1H-tetrazol-5-yl Chemical group 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933.0 | 2019-05-28 | ||
| US62/853,533 | 2019-05-28 | ||
| EP19176933 | 2019-05-28 | ||
| CNPCT/CN2020/085720 | 2020-04-20 | ||
| CN2020085720 | 2020-04-20 | ||
| PCT/US2020/034643 WO2020243135A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535734A JP2022535734A (ja) | 2022-08-10 |
| JPWO2020243135A5 true JPWO2020243135A5 (https=) | 2023-06-05 |
| JP2022535734A5 JP2022535734A5 (https=) | 2023-06-05 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570274A Pending JP2022535734A (ja) | 2019-05-28 | 2020-05-27 | 縮合複素環誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116744927A (zh) * | 2020-12-02 | 2023-09-12 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物及其在治疗hbv感染中的用途 |
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| WO2022253255A1 (en) * | 2021-06-02 | 2022-12-08 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| CN117715909A (zh) | 2021-06-02 | 2024-03-15 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物 |
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| RU2742305C2 (ru) * | 2014-12-30 | 2021-02-04 | Новира Терапьютикс, Инк. | Производные и способы лечения инфекций гепатита в |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| JP6935434B2 (ja) * | 2016-06-29 | 2021-09-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用 |
| SG11202111236UA (en) * | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111788204B (zh) | 作为hbv复制抑制剂的取代吡咯嗪化合物 | |
| KR102224081B1 (ko) | 치환된 피롤리진 화합물 및 그의 용도 | |
| KR102635333B1 (ko) | Pd-1/pd-l1 억제제 | |
| KR102522886B1 (ko) | Pd-1/pd-l1 억제제 | |
| CN115667255B (zh) | 卤代杂芳基和其他杂环激酶抑制剂及其用途 | |
| TW201927766A (zh) | Hiv蛋白酶抑制劑 | |
| JP2021532154A (ja) | 抗ｈｉｖ化合物 | |
| JP2024525160A (ja) | Ｐｄ－ｌ１を標的とするための方法及び組成物 | |
| JP2011509309A5 (https=) | ||
| TWI846853B (zh) | 吡咯化合物 | |
| CA2969417A1 (en) | Bromodomain inhibitor as adjuvant in cancer immunotherapy | |
| JP2014508720A5 (https=) | ||
| JP2019507114A5 (https=) | ||
| TW200302822A (en) | 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors | |
| TW201245144A (en) | Novel compounds useful for the treatment of metabolic and inflammatory diseases | |
| US20230133504A1 (en) | Method of treating graft-versus-host disease | |
| JPWO2020243135A5 (https=) | ||
| JP4774995B2 (ja) | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 | |
| JPWO2021214117A5 (https=) | ||
| JPWO2019213570A5 (https=) | ||
| RU2021136240A (ru) | Сочлененные гетероциклические производные | |
| HK40032660B (en) | Substituted pyrrolizine compounds as hbv replication inhibitors | |
| RU2021138956A (ru) | Сочлененные гетероциклические производные в качестве противовирусных средств | |
| RU2021135577A (ru) | Амидные производные, применимые в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv | |
| WO2025235957A1 (en) | P53 mutant stabilizer and uses thereof |